

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, D.C.

In the Matter of

**CERTAIN OVER-THE-COUNTER
TOPICAL LIDOCAINE PATCHES**

Investigation No. 337-TA-1498

**NOTICE OF COMMISSION DETERMINATION NOT TO REVIEW AN INITIAL
DETERMINATION TERMINATING THE INVESTIGATION AS TO TWO
RESPONDENTS BASED ON WITHDRAWAL OF THE COMPLAINT**

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination (“ID”) (Order No. 8) of the chief presiding administrative law judge (“CALJ”) that terminates respondents Hisamitsu U.S., Inc. (“Hisamitsu US”) of Florham, New Jersey and Opella North America (“ONA”) of Morristown, New Jersey from the above-captioned investigation based on withdrawal of the complaint. Hisamitsu US and ONA are terminated from the investigation.

FOR FURTHER INFORMATION CONTACT: Richard P. Hadorn, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street, S.W., Washington, D.C. 20436, telephone (202) 205-3179. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its Internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on April 14, 2026, based on a complaint filed by J.A.R. Laboratories LLC (“JAR”) of Lake Forest, Illinois. 91 FR 19203 (Apr. 14, 2026). The complaint, as supplemented, alleges violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based on the importation into the United States, the sale for importation, and the sale within the United States after importation of certain over-the-counter topical lidocaine patches by reason of the infringement of certain claims of U.S. Patent No. 12,109,181. *Id.* The complaint further alleges that a domestic industry exists. *Id.* The notice of investigation names 13 respondents: Veridian Healthcare LLC of Gurnee, Illinois; Perrigo Company plc of Dublin, Ireland; Perrigo Company of Allergan, Michigan; Perrigo Direct, Inc. of Peachtree City, Georgia; Opella Healthcare Group SAS of

Neuilly-sur-Seine, France; ONA; Chattem, Inc. of Chattanooga, Tennessee; Hisamitsu Pharmaceutical Co., Inc. of Tosu, Japan; Hisamitsu US; Hisamitsu America, Inc. of Florham, New Jersey; Reckitt Benckiser Group PL of Slough, United Kingdom; Reckitt Benckiser LLC of Parsippany, New Jersey; and RB Health LLC of Parsippany, New Jersey. *Id.* The Office of Unfair Import Investigations is not named as a party. *Id.*

On June 5, 2026, JAR filed a motion to terminate the investigation as to respondents Hisamitsu US and ONA based on withdrawal of the complaint. The motion states that Hisamitsu US and ONA do not oppose the motion. No responses to the motion were filed.

On June 18, 2026, the CALJ issued the subject ID (Order No. 8) granting the motion. The ID finds that the motion complies with the requirements of Commission Rule 210.21(a)(1) (19 CFR 210.21(a)(1)), and that “there are no extraordinary circumstances that warrant denying the motion.” ID at 1-2. No petitions for review of the subject ID were filed.

The Commission has determined not to review the subject ID. The investigation is hereby terminated as to Hisamitsu US and ONA.

The Commission vote for this determination took place on July 1, 2026.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR Part 210).

By order of the Commission.



Lisa R. Barton
Secretary to the Commission

Issued: July 2, 2026